Treatment With Hydroxychloroquine in Patients With Covid-19. Experience of a Neurology Department

Davidescu, Eugenia Irene; Odajiu, Irina; Bunea, Teodora; Sandu, Georgiana; Stratan, Laurențiu; Aramă, Victoria; Popescu, Bogdan Ovidiu

doi:10.31925/farmacia.2020.4.3

Cited by 8 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID-19 was first identified in late 2019 in Wuhan, the capital of Hubei Province in China, in patients who developed pneumonia without being able to establish a clear cause [ 4 ]. There are no specific treatments for COVID-19 infection yet, although many candidate therapies are being evaluated in clinical trials [ [5] , [6] , [7] , [8] ] and several COVID-19 vaccines are approved or under evaluation for approval by authorities [ [9] , [10] , [11] ]. Initially, social distancing, along with increasing population testing, are the only effective measures to control the pandemic but with several consequences on long-term [ [12] , [13] , [14] ].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 pandemic and alcohol consumption: Impacts and interconnections

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

COVID-19 pandemic and alcohol consumption: Impacts and interconnections

et al. 2021

View full text Add to dashboard Cite

show abstract

“…All patients received a course of intravenous immunoglobulins (0.4 g/kg per day for five days), two requiring plasma exchange (before the course of intravenous immunoglobulins). The SARS-CoV-2 infection was managed with antivirals such as remdesivir or favipiravir (five patients) and immunosuppressants such as tocilizumab (one patient) [ 20 ] and hydroxychloroquine (one patient) [ 21 ] according to local guidelines, as directed by the infectionist. Additional therapy with dexamethasone was administered to patients with clinically significant pulmonary involvement (four cases).…”

Section: Resultsmentioning

confidence: 99%

COVID-19 Associated Guillain–Barré Syndrome: A Report of Nine New Cases and a Review of the Literature

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Guillain–Barré syndrome (GBS)—a rare condition characterized by acute-onset immune-mediated polyneuropathy—has been registered as a neurological manifestation of COVID-19, suggesting a possible link between these two conditions. Methods: We report a case series of patients with COVID-19-related GBS hospitalized in the Neurology Department of Colentina Clinical Hospital, Bucharest, Romania, between March 2020 and March 2021. Several variables were analyzed, such as the mean interval between the onset of COVID-19 symptoms and neurological ones, clinical features, treatment course, and outcome. Further on, we conducted a thorough literature review based on the PubMed and ScienceDirect scientific databases. Results: A total of 9 COVID-19 patients developed symptoms of GBS, out of which in 7, it manifested as an acute inflammatory demyelinating polyneuropathy (AIDP). Five patients presented respiratory failure, 2 requiring mechanical ventilation. All patients received a course of intravenous immunoglobulins, 2 additionally requiring plasma exchange. Upon discharge, all but 1 patient (who had not regained the ability to walk) had a positive outcome, and 1 died during admission. In the literature review, we analyzed the published sources at the time of writing. Conclusions: A link between COVID-19 and GBS might be possible; therefore, increased vigilance is required in the early identification of these cases for prompt diagnosis and treatment. Some notable differences such as an earlier onset of GBS symptoms, higher respiratory dysfunction, and higher mortality rates in COVID-19 patients have been observed between the presentation of GBS in the context of COVID-19 and GBS of other causes.

show abstract

“…for the treatment of SARS-CoV-2 has revealed the prophylaxis capacity of these medications underlying with overall adverse potential outcomes 68 . One such approved drug (Chloroquine) is used for the treatment of malaria and also, one of the prominent nanomedicines and its derivative hydroxychloroquine is being used for the treatment of coronavirus disease 2019 (COVID-19) 69 .…”

Section: Protein Compound Name and Idmentioning

confidence: 99%

Identification of Plant-Based Drug-like Molecules as Potential Inhibitors against hACE2 and S-RBD of SARS-CoV-2 using Multi-step Molecular Docking and Dynamic Simulation Approach.

Parihar

Sonia

Choudhary

et al. 2022

Preprint

View full text Add to dashboard Cite

There has been considerable interest to develop effective antiviral drugs with substantial efficacy to the varying lineage of SARS-CoV-2. The plant-based bioactive molecules (phytochemicals) have proven to exhibit promising therapeutic efficacy and immune-modulatory effect due to their inherent broad-spectrum biological properties such as antioxidant, antiviral, and anti-inflammatory with minimal or no side effects. The SARS-CoV-2 infection is initiated upon recognition and binding of the spike (S) Receptor-Binding Domain (RBD) to the host cell surface receptor, human Angiotensin-Converting Enzyme 2 (hACE2). Therefore, the underlying mechanism of interaction between host cell receptors and blocking the virus-cell interaction is considered to be a promising approach for the management and treatment of COVID-19 disease. In the present study, In-silico screening of phytochemicals against two targets of SARS-CoV-2 using a multi-step molecular docking approach was investigated. Based on the Glide-XP docking score, the top 5 molecules were subjected to steered molecular dynamics (SMD) simulation for calculation of binding force, and work done to get mechanistic insight has been carried out. Further, the op 3 ligands with the highest force and work were subjected to molecular dynamics simulation and binding free energy evaluations. The results revealed that the protein-ligand complexes showed stable trajectories throughout the 100 ns simulation. Moreover, the drug likeliness predicted by pKi, LE, ADMET analysis, and Pa & Pi values suggested that the best 3 lead molecules for both the targets (ACE2: Rosavin, Isoorientin, Palasitrin) & (RBD: Cinnamtannin B1, Isoskimmiwallin, Terflavin A) have good inhibitory efficiency, better pharmacokinetics, and are non-toxic under physiological conditions. Thus, these molecules can be used as potential therapeutic drugs against SARS-CoV-2 infection.

show abstract

Treatment With Hydroxychloroquine in Patients With Covid-19. Experience of a Neurology Department

Cited by 8 publications

References 40 publications

COVID-19 pandemic and alcohol consumption: Impacts and interconnections

COVID-19 pandemic and alcohol consumption: Impacts and interconnections

COVID-19 Associated Guillain–Barré Syndrome: A Report of Nine New Cases and a Review of the Literature

Identification of Plant-Based Drug-like Molecules as Potential Inhibitors against hACE2 and S-RBD of SARS-CoV-2 using Multi-step Molecular Docking and Dynamic Simulation Approach.

Contact Info

Product

Resources

About